• Company
• GC WellBeing transfers raw materials technology to Japan
• by Jul 18, 2022 06:06am

• Opinion
• [Reporter’s View] Postponing clinical reevaluations by 1 yr
• by Lee, Tak-Sun Jul 18, 2022 06:05am

• Company
• SK’s epilepsy drug makes over ₩400 billion in 3 years
• by Chon, Seung-Hyun Jul 15, 2022 05:57am

• Company
• Keytruda adds neoadjuvant/adjuvant therapy indication
• by Jul 15, 2022 05:57am

• Company
• Daewoong expects sales of 4 new drugs to rise
• by Lee, Tak-Sun Jul 15, 2022 05:57am

• Company
• EUSA Pharma is entering the Korean market
• by Jul 15, 2022 05:57am

• Company
• Multinational companies leaving the Korean market
• by Jul 15, 2022 05:57am

• Policy
• Samsung reigns over Avastin biosimilar market in Korea
• by Lee, Tak-Sun Jul 14, 2022 05:54am

• Company
• Tabrecta can be prescribed at hospitals
• by Eo, Yun-Ho Jul 14, 2022 05:54am

• Policy
• No social distancing obligations are introduced
• by Lee, Jeong-Hwan Jul 14, 2022 05:54am